Data Bolster Dual Antithrombotic Therapy in AF PCI Patients Data Bolster Dual Antithrombotic Therapy in AF PCI Patients
A new study supports forgoing traditional triple antithrombotic therapy with aspirin for dual therapy with dabigatran and a P2Y12 inhibitor in patients with atrial fibrillation who ' ve undergone PCI.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 20, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news
When two is better than three: Dual antithrombotic therapy cuts bleeding risk
(Brigham and Women's Hospital) Clinical trial finds that dabigatran dual therapy after stenting reduced bleeding risk for patients with atrial fibrillation compared with standard triple therapy. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 27, 2017 Category: International Medicine & Public Health Source Type: news
PodMed: A Medical News Roundup From Johns Hopkins (with audio)
(MedPage Today) -- This week ' s topics include antibody depletion for kidney transplantation, a way to reverse dabigatran, the costs of board certification, and opioid use in the U.S. population (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - August 5, 2017 Category: Psychiatry Source Type: news
FDA Drug Safety Communication: Special storage and handling requirements must be followed for Pradaxa (dabigatran etexilate mesylate) capsules
[03-29-2011] The U.S. Food and Drug Administration (FDA) is alerting the public to important storage and handling requirements for Pradaxa (dabigatran etexilate mesylate) capsules. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 4, 2017 Category: Drugs & Pharmacology Source Type: news
Thomas Jefferson Researcher Publishes Study Showing Treatment Rapidly...
A new treatment rapidly removes the oral blood thinner dabigatran (PRADAXA®) from circulation within minutes, allowing life-saving clots to form normally(PRWeb July 18, 2017)Read the full story at http://www.prweb.com/releases/2017/07/prweb14497643.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - July 18, 2017 Category: Pharmaceuticals Source Type: news
Idarucizumab Shows Reliable Reversal of Dabigatran
Effective for dabigatran reversal among patients with uncontrolled bleeding, undergoing urgent surgery (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - July 13, 2017 Category: Respiratory Medicine Tags: Cardiology, Family Medicine, Geriatrics, Gynecology, Internal Medicine, Critical Care, Emergency Medicine, Nursing, Oncology, Orthopedics, Pharmacy, Pulmonology, Surgery, Anesthesiology & Pain, Conference News, Source Type: news
Rapid Reversal of Dabigatran Anticoagulation With Idarucizumab Rapid Reversal of Dabigatran Anticoagulation With Idarucizumab
Idarucizumab rapidly and consistently reverses the anticoagulant effect of oral agent dabigatran, aiding patients with bleeds and allowing emergency invasive procedures, the RE-VERSE AD study shows.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 13, 2017 Category: Consumer Health News Tags: Cardiology News Source Type: news
Idarucizumab Confirmed to Work as NOAC Reversal Agent (CME/CE)
(MedPage Today) -- Full cohort findings detail rapid effects independent of circulating dabigatran (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - July 11, 2017 Category: Cardiology Source Type: news
Treatment rapidly reverses the effect of blood thinner dabigatran
At least 28 million prescriptions for blood thinners are filled by pharmacists yearly for the irregular heartbeat of atrial fibrillation, deep vein thrombosis, and other indications, according to the Department of Health and Human Services. However, on rare occasions, anticoagulants can present risks of accidental bleeding and hemorrhage or can delay emergency surgery. A newly completed phase III clinical study demonstrates the safety and efficacy of idarucizumab, a novel therapy that acts as an antidote to the blood thinner dabigatran. (Source: World Pharma News)
Source: World Pharma News - July 11, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news
Treatment rapidly reverses the effect of blood thinner dabigatran
(Thomas Jefferson University) A new treatment rapidly removes the oral blood thinner dabigatran (PRADAXA ® ) from circulation within minutes, allowing life-saving clots to form normally. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 11, 2017 Category: International Medicine & Public Health Source Type: news
Safety and Efficacy of Dabigatran Reversal Agent Confirmed (FREE)
By Amy Orciari Herman
Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD
Idarucizumab — a humanized monoclonal antibody approved to reverse the anticoagulant effects of dabigatran — acts quickly and safely in emergency situations, according to final … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - July 11, 2017 Category: Primary Care Source Type: news
Dabigatran reduces resource use versus warfarin but not costs
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 30, 2017 Category: Drugs & Pharmacology Source Type: news
Pradaxa (Dabigatran Etexilate Mesylate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 5, 2017 Category: Drugs & Pharmacology Source Type: news
All About Dabigatran Reversal in the ED
(MedPage Today) -- Agent now available for reversing new oral anticoagulant in bleeding patients (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - April 15, 2017 Category: American Health Source Type: news
Mar 31 Cardiology News Mar 31 Cardiology News
High-sensitivity troponin testing, dabigatran during AF ablation, valve-in-valve TAVR, Impella, and the ARNI valsartan/sacubitril ' s effect on HbA1c are discussed in this week ' s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 31, 2017 Category: Cardiology Tags: Cardiology News Source Type: news
